Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125035 | 0.98 | FFAR3 (0.39) | FFAR3ALDH1A1SMN1; SMN2P2RX7NPSR1 | |
| SCHEMBL27419338 | 0.83 | FFAR3 (0.37) | FFAR3ALDH1A1SMN1; SMN2P2RX7NPSR1 | |
| SCHEMBL2005167 | 0.81 | FFAR3 (0.36) | FFAR3ALDH1A1SMN1; SMN2P2RX7NPSR1 | |
| SCHEMBL1439598 | 0.78 | FFAR3 (0.33) | FFAR3ALDH1A1SMN1; SMN2P2RX7CETP | |
| SCHEMBL1439274 | 0.78 | FFAR3 (0.33) | FFAR3ALDH1A1SMN1; SMN2P2RX7CETP | |
| SCHEMBL7739592 | 0.77 | ALDH1A1 (0.45) | FFAR3ALDH1A1SMN1; SMN2P2RX7NPSR1 | |
| SCHEMBL28000867 | 0.76 | FFAR3 (0.39) | FFAR3 | |
| SCHEMBL1439146 | 0.75 | FFAR3 (0.34) | FFAR3ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL1440917 | 0.75 | FFAR3 (0.34) | FFAR3ALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL31443223 | 0.75 | CYP3A4 (0.40) | FFAR3ALDH1A1SMN1; SMN2P2RX7NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | claimed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | FFAR3 3398/4885ALDH1A1 1161/4885SMN1; SMN2 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.